SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 101 filers reported holding SPERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,421 | -62.0% | 20,183 | -54.5% | 0.00% | – |
| Q2 2023 | $64,321 | +67.1% | 44,359 | +67.1% | 0.00% | – |
| Q1 2023 | $38,489 | -83.9% | 26,544 | -80.8% | 0.00% | – |
| Q4 2022 | $239,517 | -45.9% | 138,449 | -37.3% | 0.00% | – |
| Q3 2022 | $443,000 | +1007.5% | 220,986 | +308.1% | 0.00% | – |
| Q2 2022 | $40,000 | -93.2% | 54,145 | -19.3% | 0.00% | – |
| Q1 2022 | $584,000 | -84.0% | 67,084 | -70.5% | 0.00% | – |
| Q4 2021 | $3,640,000 | +73.7% | 227,366 | +99.9% | 0.00% | – |
| Q3 2021 | $2,095,000 | +57.8% | 113,748 | +19.5% | 0.00% | – |
| Q2 2021 | $1,328,000 | -34.7% | 95,158 | -31.2% | 0.00% | – |
| Q1 2021 | $2,035,000 | -62.6% | 138,283 | -50.7% | 0.00% | – |
| Q4 2020 | $5,440,000 | +476.9% | 280,556 | +232.0% | 0.00% | – |
| Q3 2020 | $943,000 | +73.0% | 84,508 | +110.0% | 0.00% | – |
| Q2 2020 | $545,000 | +365.8% | 40,250 | +263.8% | 0.00% | – |
| Q3 2019 | $117,000 | – | 11,063 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |